Genentech, Inc.

23andme, Inc.

Genetech, Inc.

Patrick Koenig

Germaine G Fuh

Chingwei Vivian Lee

Amin Famili

Karthikan Rajagopal

Yu Chen

Wei-Jen Chung

Joel Benjamin

Shashank Bharill

Mauro Poggio

Zahra Bahrami Dizicheh

Claus Spitzfaden

Shruti Yadav

Yujie Liu

I-Ling Chen

Ping-Chiao Tsai

The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Optimized variants of anti-VEGF antibodies

The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Anti-ULBP6 antibodies

The invention provides dual specific antibodies capable of binding interleukin 4 (IL4) and interleukin 5 (IL5) and methods of making and using such antibodies. In general, the dual specific antibodies capable of binding IL4 and IL5 are generated by identification of a monospecific antibody having light chain variable region Vresidues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the Vof the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the Vof the antibody. The altered Vand the Vare expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected.

Dual specific antibodies for binding interleukin 4 (IL4) and interleukin 5 (IL5)

The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).

Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer

Conjugates comprising a vascular endothelial growth factor (VEGF) antibody and a hyaluronic acid polymer

Polynucleotides encoding optimized variants of anti-VEGF antibodies

Optimized variants of anti-vegf antibodies and methods of use thereof in treatment

The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region Vresidues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the Vof the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the Vof the antibody. The altered Vand the Vare expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

Dual specific antibodies

Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis

Growing community of inventors

San Francisco, CA, United States of America

Patrick Koenig